A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0.001% for the Treatment of Patients With Dry Eye Disease (DELTA-1 Study)
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Fonadelpar (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms DELTA-1 Study
- Sponsors Senju Pharmaceutical
- 21 Nov 2018 Status changed from not yet recruiting to recruiting.
- 30 May 2018 Planned initiation date changed from 14 May 2018 to 31 Aug 2018.
- 22 May 2018 New trial record